CytoMed Therapeutics Limited (GDTC)
| Market Cap | 10.38M -53.4% |
| Revenue (ttm) | 609,727 +8.1% |
| Net Income | -2.71M |
| EPS | -0.23 |
| Shares Out | 11.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,482 |
| Open | 0.8700 |
| Previous Close | 0.8599 |
| Day's Range | 0.8700 - 0.8700 |
| 52-Week Range | 0.6801 - 3.6800 |
| Beta | 0.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About GDTC
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company’s lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural ... [Read more]
Financial Performance
In 2025, CytoMed Therapeutics's revenue was 860,848, an increase of 71.02% compared to the previous year's 503,372. Losses were -3.98 million, 58.2% more than in 2024.
Financial numbers in SGD Financial StatementsNews
Cytomed Therapeutics receives noncompliance notification from Nasdaq
CytoMed Therapeutics (GDTC) announced that the company received a notice from the staff of Nasdaq stating that for the last 30 consecutive business days, the closing bid price of the…
CytoMed Therapeutics Annual report: H2 2025
CytoMed Therapeutics has published its H2 2025 annual report on March 31, 2026.
Cytomed Therapeutics refutes ‘misleading’ claims, reaffirms clinical progress
CytoMed Therapeutics (GDTC) issued a statement to address recent statements containing “inaccurate and misleading” claims regarding the Company’s research programs, clinical progress, and operations.T...
Cytomed sees ‘enough resources’ to continue activites for ‘at least a year’
CytoMed Therapeutics (GDTC) updates shareholders as the company enters a new year in 2026. The company said, “As mentioned in previous announcements, CytoMed through new subsidiary LongevityBank is al...
Cytomed Therapeutics enters into MoU with UMMC
CytoMed Therapeutics (GDTC) announced that it has entered into a Memorandum of Understanding, MoU, with Universiti Malaya Medical Centre, UMMC, a teaching hospital under Universiti Malaya to establish...
CytoMed completes acquisition of T cell technology of TC BioPharm
CytoMed Therapeutics (GDTC) announced that it has completed with full payment the acquisition of the allogeneic gamma delta T cell technology of TC BioPharm, a subsidiary of TC BioPharm (TCBP).
Cytomed Therapeutics secures investment for subsidiary LongevityBank
CytoMed Therapeutics (GDTC) secures non-dilutive investment for its subsidiary, LongevityBank from ICH Capital. Following the announcement dated August 28, 2025, the strategic vision is for LongevityB...
Cytomed Therapeutics chairman Peter Choo increases holdings to 21.95%
CytoMed Executive Chairman and substantial shareholder, Peter Choo has increased his shareholding in the Company through recent open-market purchases of 105,824 shares. This is on top of 187,500 share...
Cytomed announces cash bid for potential acquisition of TC BioPharm
CytoMed Therapeutics (GDTC) announced that it has submitted a cash bid for an undisclosed sum with Michael Magnay and Rob Croxen of Alvarez and Marsal Europe LLP who were appointed…
CytoMed Therapeutics Earnings Call Transcript: H1 2025
Revenue doubled to SGD 156,000 for H1 2025, driven by new blood banking services, but net loss widened to SGD 2.25 million. Clinical pipeline advanced, with new collaborations and financing initiatives, while cash balances declined.
CytoMed Therapeutics Earnings release: H1 2025
CytoMed Therapeutics released its H1 2025 earnings on October 2, 2025, summarizing the period's financial results.
Cytomed Therapeutics announces publication of research on T cells
CytoMed Therapeutics (GDTC) announces the publication of a preclinical study, in a research article entitled “Donor-Derived Vgamma9Vdelta2 T Cells for Acute Myeloid Leukemia: A Promising “off-the-shel...
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
SINGAPORE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its ...
Cytomed Therapeutics expanded into auto-immune diseases
CytoMed Therapeutics (GDTC) announces it has successfully expanded clinical-scale natural killer, NK, cells from cord blood units that have been cryopreserved for more than a decade. This sets the imp...
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its ...
Cytomed Therapeutics announces $4.3M at-the-market offering program
CytoMed Therapeutics (GDTC) is pleased to announce that it entered into an At-the-Market Sales Agreement with R.F. Lafferty & Co., Inc., as the sales agent. Pursuant to the Sales Agreement,…
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its ...
Cytomed Therapeutics completes dose level 1 of ANGELICA trial
CytoMed Therapeutics (GDTC) announced the completion of dose level 1 for its first-in-human Phase I dose-escalation clinical trial for four late stage cancer patients and is scheduled to start dose…
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based...
Cytomed Therapeutics files $50M mixed securities shelf
16:19 EDT Cytomed Therapeutics (GDTC) files $50M mixed securities shelf
CytoMed Therapeutics Registration statement: Registration Filing
CytoMed Therapeutics filed a registration statement on June 13, 2025, providing details about a securities offering with the SEC.
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing...
CytoMed Therapeutics Earnings release: H2 2024
CytoMed Therapeutics released its H2 2024 earnings on April 28, 2025, summarizing the period's financial results.
CytoMed Therapeutics Annual report: H2 2024
CytoMed Therapeutics has published its H2 2024 annual report on April 28, 2025.
Cytomed Therapeutics anticipates readout of ANGELICA trial mid-year
CytoMed Therapeutics (GDTC) released a letter to shareholders, which read in part, “Looking ahead to 2025, an important milestone is our initial clinical readout of our ANGELICA trial anticipated by…